TrialNature medicine2025

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.